Nxera Pharma Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 4565.T | JAZZ | AXSM | NMRA | ACAD | XENE | |
|---|---|---|---|---|---|---|
| Market cap | 158.60B | 15.06B | 7.21B | 106.35M | 3.70B | 3.80B |
| P/E (TTM) | — | 69.4 | — | — | 9.6 | — |
| Forward P/E | 38.6 | 9.1 | 34.0 | -0.9 | 23.3 | -8.3 |
| Price/book | 2.5 | 3.6 | 68.3 | 2.4 | 3.0 | 3.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +93.88% | +75.05% | −1.73% | −78.06% | −0.83% | +2.32% |
| Today | +13.75% | +2.14% | −1.87% | −0.86% | +4.38% | +2.51% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 4565.T news ›Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
About Inflammatory Bowel Disease LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations +81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected]…
Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call Transcript
Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call October 30, 2026 4:00 AM EDT Hironoshin Nomura - Executive Officer & CFOChris Cargill - Representative Executive Officer, President, CEO & ChairmanToshihiro Maeda - President of Nxera…
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
Tokyo, Japan and Cambridge, UK, 7August 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June 2026. The full report…
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
Tokyo, Japan and Cambridge, UK, 22October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has submitted a Marketing Authorization Application (MAA) to the Ministry of Food and Drug Safety (MFDS) in South Korea…
Nxera Pharma (SOLTF) Expected to Post Quarterly Earnings on Friday
Posted by Kim Johansen on Oct 28th, 2026 Nxera Pharma (OTCMKTS:SOLTF – Get Free Report) is expected to be issuing its resultson Friday, October 30th. Analysts expect Nxera Pharma to post earnings of $0.0032 per share and revenue of $51.94…
From the 4Search news index, newest first.
In the news
Mentioned with
Most coverage from
- markets.businessinsider.com3
- seekingalpha.com2
- daily-tribune.com1
- mycarrollcountynews.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.